Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. / Torekov, S S; Madsbad, S; Holst, Jens Juul.

I: Obesity Reviews, Bind 12, Nr. 8, 2011, s. 593-601.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Torekov, SS, Madsbad, S & Holst, JJ 2011, 'Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential', Obesity Reviews, bind 12, nr. 8, s. 593-601. https://doi.org/10.1111/j.1467-789X.2011.00860.x

APA

Torekov, S. S., Madsbad, S., & Holst, J. J. (2011). Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. Obesity Reviews, 12(8), 593-601. https://doi.org/10.1111/j.1467-789X.2011.00860.x

Vancouver

Torekov SS, Madsbad S, Holst JJ. Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. Obesity Reviews. 2011;12(8):593-601. https://doi.org/10.1111/j.1467-789X.2011.00860.x

Author

Torekov, S S ; Madsbad, S ; Holst, Jens Juul. / Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. I: Obesity Reviews. 2011 ; Bind 12, Nr. 8. s. 593-601.

Bibtex

@article{c9488145c1a542deaad2ab8422abfcb3,
title = "Obesity - an indication for GLP-1 treatment?: Obesity pathophysiology and GLP-1 treatment potential",
abstract = "Obesity is common and associated with a high rate of morbidity and mortality; therefore, treatment is of great interest. At present, bariatric surgery is the only truly successful treatment of severe obesity. Mimicking one of the effects of bariatric surgery, namely the increased secretion of glucagon-like peptide (GLP)-1, by artificially increasing the levels of GLP-1 might prove successful as obesity treatment. Recent studies have shown that GLP-1 is a physiological regulator of appetite and food intake. The effect on food intake and satiety is preserved in obese subjects and GLP-1 may therefore have a therapeutic potential. The GLP-1 analogues result in a moderate average weight loss, which is clinically relevant in relation to reducing the risk of type 2 diabetes and cardiovascular disease. Inspired by the hormone profile after gastric bypass, a future strategy in obesity drug development could be to combine several hormones, and thereby produce a superior appetite suppressing hormone profile that may result in a weight loss exceeding that seen in single-agent trials. In conclusion, with the GLP-1 analogues combining a moderate weight loss with beneficial effects on metabolic and cardiovascular risk factors, it seems that we are on the right track for future treatment of obesity.",
keywords = "Animals, Appetite, Bariatric Surgery, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Eating, Glucagon-Like Peptide 1, Humans, Obesity, Risk Factors, Satiation, Weight Loss",
author = "Torekov, {S S} and S Madsbad and Holst, {Jens Juul}",
note = "{\circledC} 2011 The Authors. obesity reviews {\circledC} 2011 International Association for the Study of Obesity.",
year = "2011",
doi = "10.1111/j.1467-789X.2011.00860.x",
language = "English",
volume = "12",
pages = "593--601",
journal = "Obesity Reviews",
issn = "1467-7881",
publisher = "Wiley-Blackwell",
number = "8",

}

RIS

TY - JOUR

T1 - Obesity - an indication for GLP-1 treatment?

T2 - Obesity pathophysiology and GLP-1 treatment potential

AU - Torekov, S S

AU - Madsbad, S

AU - Holst, Jens Juul

N1 - © 2011 The Authors. obesity reviews © 2011 International Association for the Study of Obesity.

PY - 2011

Y1 - 2011

N2 - Obesity is common and associated with a high rate of morbidity and mortality; therefore, treatment is of great interest. At present, bariatric surgery is the only truly successful treatment of severe obesity. Mimicking one of the effects of bariatric surgery, namely the increased secretion of glucagon-like peptide (GLP)-1, by artificially increasing the levels of GLP-1 might prove successful as obesity treatment. Recent studies have shown that GLP-1 is a physiological regulator of appetite and food intake. The effect on food intake and satiety is preserved in obese subjects and GLP-1 may therefore have a therapeutic potential. The GLP-1 analogues result in a moderate average weight loss, which is clinically relevant in relation to reducing the risk of type 2 diabetes and cardiovascular disease. Inspired by the hormone profile after gastric bypass, a future strategy in obesity drug development could be to combine several hormones, and thereby produce a superior appetite suppressing hormone profile that may result in a weight loss exceeding that seen in single-agent trials. In conclusion, with the GLP-1 analogues combining a moderate weight loss with beneficial effects on metabolic and cardiovascular risk factors, it seems that we are on the right track for future treatment of obesity.

AB - Obesity is common and associated with a high rate of morbidity and mortality; therefore, treatment is of great interest. At present, bariatric surgery is the only truly successful treatment of severe obesity. Mimicking one of the effects of bariatric surgery, namely the increased secretion of glucagon-like peptide (GLP)-1, by artificially increasing the levels of GLP-1 might prove successful as obesity treatment. Recent studies have shown that GLP-1 is a physiological regulator of appetite and food intake. The effect on food intake and satiety is preserved in obese subjects and GLP-1 may therefore have a therapeutic potential. The GLP-1 analogues result in a moderate average weight loss, which is clinically relevant in relation to reducing the risk of type 2 diabetes and cardiovascular disease. Inspired by the hormone profile after gastric bypass, a future strategy in obesity drug development could be to combine several hormones, and thereby produce a superior appetite suppressing hormone profile that may result in a weight loss exceeding that seen in single-agent trials. In conclusion, with the GLP-1 analogues combining a moderate weight loss with beneficial effects on metabolic and cardiovascular risk factors, it seems that we are on the right track for future treatment of obesity.

KW - Animals

KW - Appetite

KW - Bariatric Surgery

KW - Cardiovascular Diseases

KW - Diabetes Mellitus, Type 2

KW - Eating

KW - Glucagon-Like Peptide 1

KW - Humans

KW - Obesity

KW - Risk Factors

KW - Satiation

KW - Weight Loss

U2 - 10.1111/j.1467-789X.2011.00860.x

DO - 10.1111/j.1467-789X.2011.00860.x

M3 - Journal article

C2 - 21401851

VL - 12

SP - 593

EP - 601

JO - Obesity Reviews

JF - Obesity Reviews

SN - 1467-7881

IS - 8

ER -

ID: 38531259